Inclusion Criteria:

• Each subject qualified by entry criteria history in a brief phone interview will be invited to come to a screening visit. A brief history and targeted physical exam to detect inclusion and exclusion criteria, listed below, will be performed after obtaining informed consent. Then, if the subject still appears eligible, they will undergo allergy skin testing to perennial ryegrass pollen extract as a key inclusion criteria. Skin testing will utilize standard prick techniques with appropriate saline/glycerin controls. The cross sectional measurements of the wheal and flare reaction will be recorded. A positive test will require a wheal >3mm vs the control diluent.

Inclusion Criteria:

• at least a 2-year clinical history of springtime allergic rhinitis
• allergy to grass pollen, defined by positive case history and positive skin prick test
• Males or non-pregnant, non-lactating females who are post-menopausal or naturally or surgically sterile
• Females of childbearing potential should be using acceptable birth control methods
• Patients who are normally active and otherwise judged to be in good health
• Patients must be willing and able to give written informed consent and must provide this consent
• Patients must be willing and able to attend required study visits
• Patients must be able to follow instructions
• Off allergy medication for at least one month prior to study entry (nasal corticosteroids, nasal azelastine, cromolyn sodium, IPRATROPRIUM bromide, antihistamines, leukotriene antagonists)

Exclusion Criteria:

• History of nasal deviation

  • Current cigarette smoker
  • History of allergy symptoms August to January
  • History of nasal polyposis
  • History of asthma
  • Concurrent disease that might complicate or interfere with investigation or evaluation of the study medications
  • Concurrent use of any prohibited medication(s)
  • Chronic or intermittent use of inhaled, oral, intramuscular, intravenous, or potent or super-potent topical corticosteroids
  • Chronic use of long acting antihistamines and other concomitant medications that would affect assessment of the effectiveness of study drug(s)
  • Any systemic disorder that could interfere with the evaluation of the study medication(s)
  • Upper or lower respiratory infection requiring antibiotics within 14 days of the first visit
  • Diagnosis of sinusitis within 30 days of the first Baseline visit
  • Hypersensitivity to the study supplement tablet fillers
  • active or quiescent tuberculosis infection of the respiratory tract
  • nasal septal ulcers, nasal surgery or nasal trauma within 90 days of enrollment
  • Clinical history of anaphylaxis
  • Patients with contraindications for allergy vaccines
  • Clinical history of immunodeficiency, including immunosuppressant therapy
  • Patients with contraindications to adrenaline
  • Subject is taking β-blockers
  • Clinical history of drug or alcohol abuse that would interfere with the patient's participation in the study
  • Clinical history of severe or uncontrolled cardiovascular, hepatic, renal and/or other disease/illness that could be expected to interfere with the study
  • Clinical history, or evidence, of nasolacrimal drainage system malfunction
  • Study site staff who would have access to the clinical study protocol
  • History of immunotherapy with grass pollen extract
  • Participation in any other investigational study within 30 days before entry into this study or concomitantly with this study